Beren Therapeutics P.B.C.®, a Public Benefit Corporation and parent company of Mandos LLC®, today announced that Mandos received Breakthrough Therapy Designation (BTD) from the U.S. Food and Drug ...

Beren Therapeutics P.B.C. (R), a Public Benefit Corporation and parent company of Mandos LLC (R), today announced that Mandos received Breakthrough Therapy Designation (BTD) from the U.S. Food and ...

Many investors welcomed the market’s recent decline as an opportunity to buy the dip. That’s not the best strategy, argue two ...

Discover Sennheiser HDB 630: premium wireless headphones offering exceptional sound quality, customization, and connectivity ...

For buy the dip to work, "it must be a relatively better time than normal to own stocks for a relatively modest length period going forward." There's also the other challenge of defining the rules to ...

The objective response rate (ORR) for the overall population was 80.0%, the disease control rate (DCR) was 100.0%, and the median duration of response (mDOR) was 12.2 months; the median ...

TransThera Sciences Inc. ("TransThera") announced the publication of clinical results from a US-based Phase 2 trial evaluating tinengotinib in patients with Cholangiocarcinoma (CCA) on The Lancet ...

Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into ...

Successful interim analysis triggered early stop for efficacy Topline study results to be shared at the American Epilepsy ...

Electra Therapeutics , a clinical stage biotechnology company pioneering therapies against novel targets for diseases in immunology and cancer, today announced it will present two posters on the ...

(Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to a New Drug Application ...